Incannex stock soars after positive Phase 2 results for sleep apnea drug

Published 30/07/2025, 13:34
© Reuters.

Investing.com -- Incannex Healthcare Inc. (NASDAQ:IXHL) stock rose 10% following the announcement of positive topline results from its Phase 2 clinical trial for IHL-42X, a novel oral drug candidate for obstructive sleep apnea (OSA).

The company reported that its RePOSA trial demonstrated statistically significant improvements across multiple key endpoints. Most notably, IHL-42X reduced the Apnoea-Hypopnoea Index (AHI) by up to 83% from baseline compared to placebo, with both low and high-dose groups showing significant improvements.

The trial enrolled 121 adult participants with moderate to severe OSA who received either a high dose, low dose, or placebo version of IHL-42X for 28 days. The drug also showed improvements in oxygen desaturation, patient-reported outcomes measuring sleep quality, and reduced daytime fatigue.

IHL-42X demonstrated what the company described as an "outstanding safety profile" with no serious adverse events reported during the treatment period. Treatment-emergent adverse effects were infrequent and primarily mild to moderate in severity.

"We are extremely pleased with the RePOSA trial results. The combination of statistically significant improvements across multiple endpoints and an outstanding safety profile positions IHL-42X as one of the most compelling drug candidates in the global race to bring a pharmaceutical treatment for OSA to market," said Joel Latham, CEO and President of Incannex.

The company is now preparing for an End-of-Phase 2 meeting with the FDA to discuss the path forward for Phase 3 trials and regulatory strategy. Incannex noted that OSA affects over 900 million people globally with no approved oral pharmaceutical treatments currently available.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.